Mimedx (MDXG) Net Cash Flow Growth (3y) (2014 - 2026)
Mimedx (MDXG) Net Cash Flow Growth (3y) (2014 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,719.23 Bn | 65,718.94 Bn | - | -50.33% |
| 2 | Nanobiotix | 1,933.82 Bn | 1,933.76 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 471.85 Bn | 467.06 Bn | 1.35 Bn | 38.47% |
| 5 | Vertex Pharmaceuticals | 122.29 Bn | 115.04 Bn | 2.59 Bn | 33.37% |
| 6 | Regeneron Pharmaceuticals | 70.04 Bn | 61.28 Bn | 3.31 Bn | -29.82% |
| 7 | Belite Bio | 62.06 Bn | 62.06 Bn | - | - |
| 8 | Argenx Se | 55.78 Bn | 50.60 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.47 Bn | 34.47 Bn | 959.66 Mn | 32.17% |
| 10 | Mimedx | 647.97 Mn | 488.19 Mn | 41.62 Mn | -327.94% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -327.94% |
| Dec 31, 2025 | 108.45% |
| Sep 30, 2025 | 219.02% |
| Jun 30, 2025 | 80.89% |
| Mar 31, 2025 | 29.60% |
| Dec 31, 2024 | 49.89% |
| Sep 30, 2024 | 54.61% |
| Jun 30, 2024 | 328.60% |
| Mar 31, 2024 | -44.68% |
| Dec 31, 2023 | 15.51% |
| Sep 30, 2023 | -40.68% |
| Jun 30, 2023 | 61.06% |
| Mar 31, 2023 | 82.66% |
| Dec 31, 2022 | 28.18% |
| Sep 30, 2022 | 31.13% |
| Jun 30, 2022 | -26.96% |
| Mar 31, 2022 | 12.00% |
| Dec 31, 2021 | -467.95% |
| Sep 30, 2021 | 98.13% |
| Jun 30, 2021 | -75.56% |